Results 191 to 200 of about 17,057 (320)

ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3173-3186, 15 June 2026.
What's new? Errors in DNA double‐strand break (DSB) repair can lead to mutations, chromosomal instability, and ultimately cancer. Inhibitor of DNA‐binding 3 (ID3), a transcriptional repressor, is crucial to promoting DSB repair and helping maintain genome stability. Here, the authors investigated ID3 regulation of DNA repair via chromatin accessibility
Giuditta Della Corte   +10 more
wiley   +1 more source

The diversification of PHIS transposon superfamily in eukaryotes [PDF]

open access: yes, 2015
Chu-Lin Xiong   +5 more
core   +1 more source

Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti‐PD‐L1 Efficacy in Intrahepatic Cholangiocarcinoma

open access: yesAdvanced Science, Volume 13, Issue 32, 9 June 2026.
The m6A reader YTHDF1 drives intrahepatic cholangiocarcinoma (ICC) progression by remodeling the tumor immune microenvironment. YTHDF1 promotes MDSC recruitment via activation of m6A‐FOSL2‐CXCL6/CXCR2 axis, thereby suppressing CD8+ T cell infiltration and function.
Li Luo   +14 more
wiley   +1 more source

Plant‐Derived Melatonin Inhibits Bacterial Virulence via CpxA/R Two‐Component System

open access: yesAdvanced Science, Volume 13, Issue 32, 9 June 2026.
Plant‐derived melatonin is sensed by CpxAE48/T51, which inhibits the phosphorylation cascade transmission from CpxAH240 to CpxRD52, resulting in the inhibition of DNA‐binding capacity of CpxR and subsequent T3SS genes expression in Pst DC3000. ABSTRACT In defending against pathogens, plants deploy diverse secondary metabolites and signaling molecules ...
Jin‐Wei Wei   +7 more
wiley   +1 more source

Mutational Analysis of the Mu Transposase [PDF]

open access: yesJournal of Biological Chemistry, 1998
Elena Krementsova   +3 more
openaire   +1 more source

Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma

open access: yesCancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background Multiple myeloma (MM) remains the second most common hematologic malignancy, necessitating the identification of novel therapeutic targets. MM is characterized by a distinct epigenetic landscape driven by aberrant chromatin activation and super‐enhancer addiction.
Hong Xu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy